SLC5A2 and bacterial urinary tract infection: Our findings show SGLT2 inhibition compared with placebo similarly reduced the risk of major cardiovascular outcomes, improved renal parameters (estimated GFR, volume depletion, changes in albuminuria and electrolyte imbalances) and glycaemic measures (HbA1c and hypoglycaemia) and increased the risk of adverse events including genital infections and UTI in both groups of patients with and without RAAS inhibition.